Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paula Jimenez-Fonseca

Showing results (1-10 of 88) with videos related to

Pageof 9
Sort By:
Cancer Medicine|October 6, 2022
Use of multikinase inhibitors/lenvatinib in patients with high cardiovascular risk/vasculopathy and radioiodine refractory-differentiated thyroid cancerPaula Jimenez-Fonseca
Critical Reviews in Oncology/Hematology|August 20, 2013
Clinical evaluation and optimal management of cancer cachexiaAlbert Tuca, Paula Jimenez-Fonseca, Pere Gascón
The New England Journal of Medicine|May 6, 2020
A Trial of Lopinavir-Ritonavir in Covid-19Alberto Carmona-Bayonas, Paula Jimenez-Fonseca, Eduardo Castañón
Molecular Cancer Therapeutics|October 5, 2021
Olaratumab-induced Biomarker Modulation in Sarcomas-LetterVicente Valenti, Alberto Carmona-Bayonas, Paula Jimenez-Fonseca, et al.
European Journal of Internal Medicine|March 4, 2022
Medicine before and after David CoxPavlos Msaouel, Paula Jimenez-Fonseca, Bora Lim, et al.
Frontiers in Psychology|November 16, 2020
Estimation of Risk of Recurrence and Toxicity Among Oncologists and Patients With Resected Breast Cancer: A Quantitative StudyLaura Ciria-Suarez, Paula Jimenez-Fonseca, Raquel Hernández, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2020
Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settingsEduardo Castañon, Alvaro Sanchez-Arraez, Felipe Alvarez-Manceñido, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2020
Erratum to "Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings" [Eur J Cancer 136 (September 2020) 159-168]Eduardo Castañón, Alvaro Sanchez-Arraez, Felipe Alvarez-Manceñido, et al.
European Journal of Internal Medicine|June 9, 2020
Does active smoking worsen Covid-19?Alberto Carmona-Bayonas, Paula Jimenez-Fonseca, Álvaro Sánchez Arraez, et al.
Therapeutic Advances in Medical Oncology|October 3, 2022
Supplemental parenteral nutrition in cancer care: why, who, whenPaolo Cotogni, Federico Bozzetti, François Goldwasser, et al.
Pageof 9

Showing results (1-10 of 88) with videos related to

Sort By:
Pageof 9
Cancer Medicine|October 6, 2022
Use of multikinase inhibitors/lenvatinib in patients with high cardiovascular risk/vasculopathy and radioiodine refractory-differentiated thyroid cancerPaula Jimenez-Fonseca
Critical Reviews in Oncology/Hematology|August 20, 2013
Clinical evaluation and optimal management of cancer cachexiaAlbert Tuca, Paula Jimenez-Fonseca, Pere Gascón
The New England Journal of Medicine|May 6, 2020
A Trial of Lopinavir-Ritonavir in Covid-19Alberto Carmona-Bayonas, Paula Jimenez-Fonseca, Eduardo Castañón
Molecular Cancer Therapeutics|October 5, 2021
Olaratumab-induced Biomarker Modulation in Sarcomas-LetterVicente Valenti, Alberto Carmona-Bayonas, Paula Jimenez-Fonseca, et al.
European Journal of Internal Medicine|March 4, 2022
Medicine before and after David CoxPavlos Msaouel, Paula Jimenez-Fonseca, Bora Lim, et al.
Frontiers in Psychology|November 16, 2020
Estimation of Risk of Recurrence and Toxicity Among Oncologists and Patients With Resected Breast Cancer: A Quantitative StudyLaura Ciria-Suarez, Paula Jimenez-Fonseca, Raquel Hernández, et al.
European Journal of Cancer (Oxford, England : 1990)|July 23, 2020
Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settingsEduardo Castañon, Alvaro Sanchez-Arraez, Felipe Alvarez-Manceñido, et al.
European Journal of Cancer (Oxford, England : 1990)|November 9, 2020
Erratum to "Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings" [Eur J Cancer 136 (September 2020) 159-168]Eduardo Castañón, Alvaro Sanchez-Arraez, Felipe Alvarez-Manceñido, et al.
European Journal of Internal Medicine|June 9, 2020
Does active smoking worsen Covid-19?Alberto Carmona-Bayonas, Paula Jimenez-Fonseca, Álvaro Sánchez Arraez, et al.
Therapeutic Advances in Medical Oncology|October 3, 2022
Supplemental parenteral nutrition in cancer care: why, who, whenPaolo Cotogni, Federico Bozzetti, François Goldwasser, et al.
Pageof 9